Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-Label, Single Arm Pilot Study to Evaluate the Safety and Efficacy of Pembrolizumab for High-Grade Cervical Intraepithelial Neoplasia

NCT04712851 is registered in ClinicalTrials.gov with Jonsson Comprehensive Cancer Center as lead sponsor.

NCT NCT04712851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04712851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-Label, Single Arm Pilot Study to Evaluate the Safety and Efficacy of Pembrolizumab for High-Grade Cervical Intraepithelial Neoplasia
Lead sponsor
Jonsson Comprehensive Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 30, 2021
Completion date
January 31, 2028
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical intraepithelial neoplasia, cervical squamous cell carcinoma in situ, cervical squamous intraepithelial neoplasia 2